LivaNova is a London-based medical device company that develops and manufactures products for use in epilepsy treatment and interventional cardiology. With the divestiture of the company's cardiac rhythm management division now complete, we expect the firm to report in two primary segments: cardiac surgery (roughly 60% of 2017 sales) and neuromodulation (40%). We estimate that the firm's revenue mix will shift further toward the U.S. after the divestiture, with roughly 50% of total sales derived from the U.S., 20% from Europe, and 30% from the rest of the world.
